Fortress Biotech, Inc.

FBIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $6.8M $-46.0M $-60.6M $-86.6M $-64.7M $-46.5M $-40.0M $-84.1M
Depreciation & Amortization
Depreciation $403.0K $1.0M $2.2M $3.1M $2.6M $2.3M $1.9M $1.4M
Amortization $4.3M $3.4M $3.8M $4.3M $1.4M $1.2M
Stock-Based Compensation $28.7M $32.6M $17.0M $23.0M $19.5M $13.5M $13.2M $15.0M
Net Cash from Operating Activities $-65.8M $-80.2M $-128.2M $-179.4M $-116.5M $-83.7M $-95.0M $-98.8M
Investing Activities
Capital Expenditures $0 $63.0K $2.7M $4.6M $1.9M $2.3M $7.1M
Business Acquisitions
Net Cash from Investing Activities $10.1M $-15.0M $-2.1M $-22.9M $40.5M $-7.2M $20.1M $18.8M
Financing Activities
Dividends Paid $664.0K $694.0K $736.0K $749.0K $749.0K $237.0K $0
Stock Repurchases $70.0K $0
Net Cash from Financing Activities $77.4M $70.6M $32.7M $75.3M $149.0M $172.4M $146.7M $50.6M
Net Change in Cash $21.8M $-24.6M $-97.6M $-127.0M $73.0M $81.6M $71.9M $-29.4M
Free Cash Flow $-80.2M $-128.3M $-182.1M $-121.1M $-85.6M $-97.3M $-105.9M
← Newer Page 1 of 3 Older →